Ropeginterferon Alfa-2B

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Chronic Myeloid Leukemia

Conditions

Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

Trial Timeline

Mar 29, 2026 → Mar 30, 2032

NCT ID

NCT07468916

About Ropeginterferon Alfa-2B

Ropeginterferon Alfa-2B is a phase 2 stage product being developed by PharmaEssentia for Atypical Chronic Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07468916. Target conditions include Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07468916	Phase 2	Recruiting	Mar 29, 2026	Mar 30, 2032	Atypical Chronic Myeloid Leukemia
NCT06290765	Approved	Recruiting	Feb 1, 2026	Jun 30, 2027	Polycythemia Vera
NCT07047885	Phase 1	Recruiting	Aug 27, 2025	Jun 1, 2028	Cutaneous T Cell Lymphoma
NCT06468033	Phase 3	Recruiting	Jul 18, 2025	Sep 30, 2028	Primary Myelofibrosis
NCT05485948	Phase 2	Active	Oct 8, 2021	Jul 1, 2027	Polycythemia Vera
NCT03546465	Phase 1	Completed	May 7, 2018	Jul 15, 2019	Healthy Volunteers

Competing Products

18 competing products in Atypical Chronic Myeloid Leukemia

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Duloxetine	Eli Lilly	Approved	85
Teriparatide 20 mcg	Eli Lilly	Phase 3	77
Baricitinib	Eli Lilly	Pre-clinical	23
Ravulizumab	AstraZeneca	Pre-clinical	23
Eculizumab	AstraZeneca	Phase 3	77
Iptacopan	Novartis	Phase 3	77
Iptcaopan 200 mg	Novartis	Phase 3	77
Iptacopan	Novartis	Phase 3	77
CCX168	Amgen	Phase 2	51
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	40
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	49
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	49
Axatilimab + Azacitidine	Incyte	Phase 1/2	38
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	44
Apatinib Mesylate	Brain Biotech	Pre-clinical	15
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	25

Other Products from PharmaEssentia

Ropeginterferon alfa-2bApproved

Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPhase 3

P1101 + Ribavirin + PEG-Intron + RibavirinPhase 3

Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)Phase 3

Ropeginterferon alfa-2bPhase 3